Last reviewed · How we verify
PBK_M2101 2-Day
PBK_M2101 2-Day is a small molecule that targets the molecular target.
PBK_M2101 2-Day is a small molecule that targets the molecular target. Used for Phase 3 clinical trial for a specific indication.
At a glance
| Generic name | PBK_M2101 2-Day |
|---|---|
| Sponsor | Pharmbio Korea Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not well understood, but it is believed to work through a specific pathway.
Approved indications
- Phase 3 clinical trial for a specific indication
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |